Navigation Links
Mylan Wins Generic Prilosec(R) Patent Litigation
Date:6/10/2008

Court of Appeals Affirms No Infringement

PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg Omeprazole delayed-release capsules do not infringe patents asserted against Mylan by AstraZeneca. Omeprazole is the generic version of AstraZeneca LP's Prilosec(R).

Mylan launched its Omeprazole products on August 4, 2003, despite the patent infringement litigation, which at the time was unprecedented in the generic pharmaceutical industry.

"Once again, we are pleased to have prevailed in court, and we believe that this decision ends the patent litigation surrounding this product for our company," said Mylan Vice Chairman and CEO Robert J. Coury. "Our original decision to launch this product means that consumers, the government and third-party payors have benefited significantly for nearly five years because they've had access to a lower-cost generic version of Prilosec."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
2. Mylan Announces Final FDA Approval for Zaleplon Capsules
3. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
4. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
8. Mylan Announces Final FDA Approval for Trandolapril Tablets
9. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
10. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
11. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. ... healthcare bill to repeal and replace the Affordable Care Act (ACA). Like the ... significant cuts to Medicaid, a public health insurance program for low-income children, pregnant ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows ... civil society in 11 countries across the Middle East and South Asia to embark ... of knowledge and ideas with the leading minds in their fields. , For ...
(Date:6/23/2017)... Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... on 26th June, 2017 from 9 am to 3 pm to present to graduate ... The program is an original curriculum project led by The Health Improvement Service ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
Breaking Medicine Technology: